Search


Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Overview

The Medicinal |Product Form "containing" (MPF-containing) concept is containing x in y dose form (medicinal product form)| concept is an abstract representation of active ingredient(s) and dose form intended site for a medicinal product.  It means that the medicinal product must contain the The medicinal product must contain the active ingredient(s) specified in the FSN but may FSN but may also contain a modification of the active ingredient(s) specified in the FSN or may contain additional active ingredient(s) as well.Example:

For example,

    • Product containing axitinib in oral dose form (medicinal product form)
    • Product containing abacavir and lamivudine in oral dose form (medicinal product form)

Modeling

...

Stated parent concept

763158003 |Medicinal product (product)

Semantic tag(medicinal product form)
Definition status900000000000073002 |Sufficiently defined by necessary conditions definition status (core metadata concept)|

Attribute:

Has active ingredient

Range: 105590001 <105590001 |Substance (substance) - descendants only|, excluding concepts representing structural groupers, dispositions, or roles

Cardinality: 1..*

There is no technical limit on the number of Has active ingredient attributes that may be added to a concept; a practical limit may be imposed at a later date.

For content in the International Release, this attribute value should represent the base ingredient, not a modification, unless explicitly identified as an exception.

Exceptions:
  • Chemical element with multiple modification (e.g. 422232005 |Calcium lactate gluconate (substance)|)
  • Chloral hydrate (e.g. 386735001 |Product containing chloral hydrate in oral dose form (medicinal product form)|)
  • Liposome or lipid complex substances(e

    .

    g. 426490000 |Vincristine liposome (substance)|, 425953004 |Amphotericin B lipid complex (substance)|, 768664009 |Amphotericin B phospholipid complex (substance)|, 427544000 |Amphotericin B cholesteryl sulfate complex (substance)|)
  • Pegylated substance (e.g. 385544005 |Pegfilgrastim (substance)|, 770965008 |Pegvaliase (substance)|)
  • Radiopharmaceutical (e.g. 783866002 |Product containing cyanocobalamin (58-Co) in oral dose form (medicinal product form)|, 783856005 |Product containing sodium iodide (131-I) in parenteral dose form (medicinal product form)|)
  • Silver sulfadiazine (e.g. 771756000 |Product containing silver sulfadiazine in cutaneous dose form (medicinal product form)|)
  • Benzylpenicillin (e.g. 713760005 |Product containing benzathine benzylpenicillin in parenteral dose form (medicinal product form)|)

    Attribute:

    Has manufactured dose form

    Range: 736542009 |Pharmaceutical dose form (dose form) - descendants that are groupers representing intended site only (e.g. 385268001 |Oral dose form (dose form)|, 385287007 |Parenteral dose form (dose form)|)

    Cardinality: 1..1

    Exceptions: 

    • 385217004 |Conventional release gas for inhalation (dose form)| may be used as manufactured dose form for Medicinal product form concepts.
    • 785898006 |Conventional release solution for irrigation (dose form)| does not have 736474004 |Has dose form intended site (attribute)| but can be used as a target for manufactured dose form for Medicinal product form concepts.

    Naming Guidelines

    FSN

    Use the following pattern for the FSN; align naming and case sensitivity with the FSN for the concepts that are selected as the attribute value, excluding the semantic tag. For multiple ingredient drug products, the active ingredients must be in alphabetical order and separated by the word “and”.

    • Product containing <Active ingredient FSN> in <Manufactured dose form FSN> (medicinal product form)
    • Product containing <Active ingredient FSN> and <Active ingredient FSN> in <Manufactured dose form FSN> (medicinal product form)
    • Product containing <Active ingredient FSN> and <Active ingredient FSN> and <Active ingredient FSN> in <Manufactured dose form FSN> (medicinal product form)

    Creation of MPF-containing concepts for all possible combinations of active ingredients contained in multiple ingredient products is not recommended at this time (no specific use case has been identified). For example, a product containing three active ingredients would only require creation of one MPF-containing concept. If any of the active ingredients is available as a single ingredient product, or as part of another multiple ingredient concept, then appropriate concepts would be created for those products.

    For example,

        • Product containing axitinib in oral dose form (medicinal product form)
        • Product containing abacavir and lamivudine in oral dose form (medicinal product form)
        • Product containing abacavir and lamivudine and zidovudine in oral dose form (medicinal product form)

    Preferred Term

    Use the following pattern for the PT; align naming and case sensitivity with the PT for the concept that is selected as the attribute value. For multiple ingredient drug products, the active ingredients must be in alphabetical order and separated by the word “and”.

    • <Active ingredient PT>-containing product in <Manufactured dose form PT>
    • <Active ingredient PT>- and <Active ingredient PT>-containing product in <Manufactured dose form PT>
    • <Active ingredient PT>- and <Active ingredient PT>- and <Active ingredient PT>-containing product in <Manufactured dose form PT>

    For example,

        • Axitinib-containing product in oral dose form
        • Abacavir- and lamivudine-containing product in oral dose form
        • Abacavir- and lamivudine- and zidovudine-containing product in oral dose form
    Synonym

    Synonyms matching the FSN are not required.

    Exemplars

    The following illustrates the stated view for 773391004 |Product containing axitinib in oral dose form (medicinal product form)|

    ...